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Abstract
Background: Translational control is utilized as a means of regulating gene expression in many species. In most cases,
posttranscriptional regulatory mechanisms play an important role in stress response pathways and can lead to
dysfunctional physiology if blocked by mutations. Carnitine Palmitoyltransferase 1 C (CPT1C), the brain-specific member of
the CPT 1 family, has previously been shown to be involved in regulating metabolism in situations of energy surplus.
Principal Findings: Sequence analysis of the CPT1C mRNA revealed that it contains an upstream open reading frame (uORF)
in the 59 UTR of its mRNA. Using CPT1C 59 UTR/luciferase constructs, we investigated the role of the uORF in translational
regulation. The results presented here show that translation from the CPT1C main open reading frame (mORF) is repressed
by the presence of the uORF, that this repression is relieved in response to specific stress stimuli, namely glucose
deprivation and palmitate-BSA treatment, and that AMPK inhibition can relieve this uORF-dependent repression.
Significance: The fact that the mORF regulation is relieved in response to a specific set of stress stimuli rather than general
stress response, hints at an involvement of CPT1C in cellular energy-sensing pathways and provides further evidence for a
role of CPT1C in hypothalamic regulation of energy homeostasis.
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Introduction
The presence of upstream open reading frames (uORF) within
mRNA 59UTR can impact levels of translation initiation of the
main open reading frame (mORF). Because eukaryotic ribosomes
generally only initiate once per mRNA [1], the presence of an
uORF normally inhibits the translation of the mORF and may lead
to mRNA decay [2–8]. Although they are usually short sequences,
uORFs may still play critical roles in modulating physiology.
Indeed, mutations that introduce new or disrupt existing uORFs
have been reported to cause human diseases [9–11].
Carnitine Palmitoyltransferase 1 (CPT1) C is a gene of the CPT1
family that is expressed specifically in the brain under normal
conditions [12]. It is well established that CPT1A and CPT1B, the
other two CPT1 family members, catalyze the initiating step of fatty
acid degradation through which long-chain fatty acids (LCFA) are
transported from the cytoplasm to the mitochondrial matrix for b-
oxidation [13,14]. In this enzymatic reaction, the fatty acyl group is
transferred from acyl-CoA to carnitine to allow transport into
mitochondria. The fact that CPT1C is mainly expressed in the CNS
[12,15], a tissue normally not using fatty acids (FA) as a major
energy source, suggests a potentially unique function for CPT1C.
Recent publications show that CPT1C expression in the brain is
mainly restricted to the hypothalamic feeding centres, where lipid
metabolism is believed to play a key role in regulating peripheral
energy homeostasis. Results derived from studies using Cpt1c
knock-out mice implicate CPT1C in the regulation of energy
homeostasis and the control of food intake [16,17]. The
mechanisms by which CPT1C inhibition regulates feeding behavior
remain elusive. It has been established that CPT1C, like the other
CPT1 family members, binds LCFA, although the enzymatic
activity of the CPT1C transferase domain is still controversial in the
literature [15,17–19]. Intracellular accumulation of saturated
LCFA, for example palmitate, in non-adipose tissue leads to an
inhibition of proliferation and apoptosis [20–22].
The maintenance of whole body energy homeostasis is critical
for survival. This requires the presence of sensors that detect
changes in whole body energy expenditure and induce adaptive
responses. Hypothalamic feeding centers have been shown to
regulate the desire for food intake and satiety and play an
important role in the nervous system control of energy homeostasis
[15,23–27]. Hypothalamic cyclic-AMP dependent protein kinase
(AMPK) activity is tightly regulated under physiological conditions
and has been shown to play an important role in the hypothalamic
regulation of energy homeostasis. AMPK is a heterotrimeric kinase
complex composed of a catalytic a subunit and two regularly b
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and c subunits. AMPK activity is enhanced by AMP binding and
phosphorylation of the catalytic subunit by upstream kinases.
Hypothalamic AMPK is responsive to alteration in cellular energy
level, circulating hormones and nutritional cues. The modulation
of AMPK activity in response to these factors initiates signaling
pathways leading to changes in feeding behavior. These results
show that a reduction in hypothalamic AMPK activity is sufficient
to reduce food intake and body weight. In contrast, injection of the
pharmacological AMPK agonist AICAR or the expression of
constitutively active AMPK cause an increase in food intake and
body weight. The molecular mechanism(s) by which AMPK
regulates nutritional satiety involving the hypothalamus are still
largely unknown but it may function through controlling
differential hypothalamus gene expression [25,28].
FAs are also known to be involved in the nervous control of
energy homeostasis. It has been shown that free FAs are not
used as fuel for neurons but serve as informative molecules
about the whole body energy homeostasis. Specialized neurons
within the hypothalamus detect variations of FA levels in the
plasma and integrate this information in the regulation of
peripheral glucose and lipid metabolism. Inhibition of the
hypothalamic CPT1 by chemical inhibitors or the accumulation
of certain LCFAs in the hypothalamus causes a reduction of
food intake It has been hypothesized that high FA levels might
serve as a signal for sufficient feeding and thereby reduce food
intake [27,29–34].
Here, we describe the existence of a conserved uORF element
in the 59UTR of CPT1C as well as its regulation by cellular energy
sensing mechanisms. Analysis of the mRNA sequences revealed
that CPT1C is the only CPT1 member that contains an uORF
and that the presence of uORFs for Cpt1c is conserved in several
mammalian species. Experiments using luciferase reporter con-
structs transfected into brain-derived cell lines reveal that the
presence of the uORF inhibits the translation of the downstream
mORF. In addition, these experiments show that the translation
inhibition by the uORF is relieved in situations of glucose
deprivation and palmitate-BSA treatment. Finally, we demon-
strate by pharmacological and genetic interference, how AMPK
activity controls this translation repression of CPT1C.
Results
Human CPT1C mRNA contains an uORF upstream of the
mORF
The human CPT1C gene consists of 21 exons that give rise to
two transcript variants (transcript variant 1 [NM_001136052],
transcript variant 2 [NM_152359]). Although both mRNAs are
transcribed from the same gene, both transcript variants differ in
lengths and exon content. In both transcript variants exon 2 and
parts of exon 16, and in transcript variant 2 also exon 3, are not
part of the spliced mRNA. These exons, although not part of the
mRNA might, however, have a regulatory function for either
transcriptional or posttranscriptional regulation mechanisms.
Both mRNAs contain one uORF maintaining the same start
codon but stop codons derived from exon 3 and exon 4 respectively.
The uORF within transcript variant 1 starts at bp 97 and has a stop
codon at bp 198 resulting in a 34 AA long peptide. The uORF
within transcript variant 2 on the other hand starts at bp 91 and the
corresponding stop codon at bp 206 resulting in a 37 AA long
peptide. Neither of the peptides produced by the uORFs has any
similarity to known proteins or protein domains.
CPT1C is the only CPT1 family member containing an
uORF upstream of the Morf
CPT1C mRNA sequences of various species listed on NCBI
showed that all mRNAs listed contain long 59UTRs harbouring
one or several uORFs (Table 1). The sequences and number of the
mammalian CPT1C uORFs can vary significantly suggesting that
the subsequent peptide(s) are not functional. For example, whereas
the human CPT1C mRNA contains a single uORF out of frame
with the mORF, the rat Cpt1c mRNA contains three uORF’s that
are located both in frame as well as out of frame with the mORF.
Sequence analysis of resulting peptides from these uORF’s from
different species did not reveal any conserved elements except in
the closely related primate species, suggesting that the peptide
encoded does not have a conserved function. It should be noted
that no orthologues of CPT1C have been annotated as such for
non-mammalian vertebrates. To determine whether the presence
of an uORF is also a common feature of the whole CPT1 family,
we analyzed the mRNA sequences of the other two CPT1 family
members, CPT1A and CPT1B. This analysis, however, revealed
that both mRNAs have short 59 UTRs containing no similar
uORFs (Table 1). Indeed no annotated mammalian CPT1A or
CPT1B paralog contain an uORF. This conservation suggests the
CPT1C uORFs may be functional components of the mRNA that
can regulate translation of the mORF.
Effects of the CPT1C uORF on the translation of the
downstream mORF
Short uORFs can function as regulatory elements on the level of
translation [2,3,4]. The presence of the uORF in both CPT1C
transcript variants suggests that both variants can be regulated by
the same mechanism. Because of this similarity between the
transcript variants, we chose to only use the 59UTR of CPT1C
Table 1. uORF distribution and 59UTR length throughout the CPT1 family.
species Accession number 59UTR length no. uORF’s
human CPT1A NM_001876 170 bp 0
human CPT1B NM_004377 84 bp 0
human CPT1C transcript variant 1 NM_001136052 281 bp 1
human CPT1C transcript variant 2 NM_152359 206 bp 1
mus musculus cpt1c NM_153679 194 bp 2
rattus norwegicus cpt1c NM_001034925 199 bp 3
bos taurus cpt1c XM_002695120 225 bp 2
pogo abelii predicted cpt1c NM_001132026 228 bp 1
doi:10.1371/journal.pone.0021486.t001
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transcript variant 1 for further experiments. To analyse the uORF
function, we cloned the CPT1C 59UTR upstream of a luciferase
reporter from a heterologous CMV immediate early promoter. As
a negative control for non-uORF activities of the 59UTR, we also
cloned the same sequence where the start codon ATG of the
uORF was mutated to ACG (Fig. 1A). Although the point
mutation of the uORF start codon should not influence mRNA
transcription or translation, we cannot fully exclude such effects.
In order to exclude that the insertion of the CPT1C 59UTR or the
applied treadments influnce transcription or translation of the
Luciferase reporter gene we used the original vector was used as a
control in every experiment (data not shown). Transfection of
glioblastoma-derived T98G cells demonstrated that the 59UTR
containing the mutated start codon exhibit a 3-fold higher
luciferase activity than cells transfected with the 59UTR containing
the start codon (Fig. 1B). SV40-FHAS and U87-MG cells
transfected with the plasmids containing the mutated uORF also
showed an increase in luciferase activity (2.5- and 2.6-fold,
respectively) when compared to the wild type (wt) luciferase reporter
construct (Fig. S1). The difference in translation efficiency was
observed 24 h as well as 36 h after transfection. These data indicate
that the presence of the intact uORF of the CPT1C mRNA inhibits
the translation of the mORF under normal growth conditions.
Translation downstream of the CPT1C uORF is
derepressed by glucose deprivation
Most of the reported uORFs have been shown to regulate the
translation of the mORF in response to the cellular environment
[2,5,6]. Since CPT proteins are predicted to function in regulating
energy availability we chose to examine whether different
metabolic stress stimuli influenced CPTIC 59UTR activity. We
examined expression from our uORF luciferase reporter con-
structs with altered cellular environments in T98G, SV40-FHAS
and U87-MG cells.
To examine the influence of nutrient limitation on the uORF-
mediated translational repression, the cells were incubated in
media lacking glucose and/or FBS. In T98G cells the luciferase
activity was increased by 1.5 fold after 12 h and by 2-fold after
24 h glucose deprivation (Fig. 2A) compared to cells grown in
normal growth medium. Alone, FBS deprivation had no effect on
luciferase activity at either time point (Fig. 2A). In the absence of
glucose, however, FBS deprivation lead to an increase of 2-fold
after 12 and 3-fold after 24 h treatment in T98G cells (Fig. 2A)
when compared to cells grown in normal growth medium. The
change of luciferase activity in SV40-FHAS and U87-MG cells
upon treatment with the described deprivation conditions were
similar to the changes observed in T98G cells (Fig. S2). To exclude
that increased luciferase activity in response to glucose deprivation
was derived from treatment-induced changes in transcriptional
activity, cells transfected with the mutated 59UTR construct were
treated in parallel to the cells transfected with the wt 59UTR
constructed. In the absence of the intact ATG, we did not see any
changes in luciferase activity in response to the deprivation media
(Fig. 2C), suggesting that the derepression is not transcriptionally
regulated but, rather, dependent on the uORF.
To elucidate at what glucose concentration the CPT1C 59UTR
repression is lost, we performed a glucose titration on transfected
T98G cells. Because we saw little effect from the absence of FBS, we
performed a glucose titration in the presence of FBS. The first
strong increase in firefly luciferase activity can be observed at the
titration step containing 0.62 mMof glucose with a stepwise increase
of activity until the highest activity is reached in the medium
containing no glucose. The general trend of slow increase in
luciferase expression, however, suggests that glucose responsiveness
of the CPT1C 59UTR is not a tight switch but rather a concentration
sensor of glucose or some glucose-dependent metabolite(s).
To exclude that the CPT1C 59UTR is derepressed in response to
general stress pathway activation rather than mediating a specific
stress response, the cells were treated with 0.2% O2 for 12 h with or
without a 12 h reoxigenation period following the hypoxic
conditions. None of the tested hypoxia or reoxigenation conditions
led to changes in reporter activity in T98G cells (Fig. S3).
CPT1C uORF regulation is influenced by AMPK activity
To test whether derepression of the CPT1C 59UTR in response
to the cellular environment is dependent on the activation of
AMPK, the transfected cells were treated with chemical AMPK
activators and inhibitors. Additionally, we used the mTOR
inhibitor Rapamycin to investigate a potential involvement of
mTOR in potential uORF regulation.
To evaluate the effect of the chemical AMPK inhibitors
Metformin and Compound C as well as the agonist AICAR,
Figure 1. CPT1C 59UTR induces reporter gene repression. (A) Reporter gene constructs containing the CPT1C 59UTR cloned in front of a
luciferase reporter gene with either the endogenous uORF start codon (ATG) or the mutated uORF start codon (ACG). (B) Luciferase activities of uORF
start (filled bars) and uORF no start (empty bars) reporters in T98G cells after transfection and maintenance in normal conditions for 24 h or 36 h. RLU,
Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g001
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T98G cells maintained in glucose deprivation medium were
treated with the chemical compounds for 6 h. Western Blot
analysis revealed the expected increase in AMPK phosphorylation
in response to AICAR treatment (Fig. 3D). Whereas Metformin is
commonly classified as an AMPK agonist, in our study treatment
with Metformin resulted in a dose dependent decrease in AMPK
phosphorylation that was also observed in the samples treated with
Compound C (Fig. 3D). Such metformin inhibition of AMPK in
neuronal cells has been previously reported [35–38]. Treatment
with metformin, with and without glucose deprivation led to an
increase in luciferase activity in a dose-dependent manner. T98G
cells treated with 1 mM or 10 mM Metformin showed a 1.2- or 2-
fold increase, respectively, in reporter activity under glucose
deprivation conditions and a 1.6- or 3.6-fold increase, respectively,
if treated with FBS deprivation (Fig. 3B). Consistent with AMPK
positively activating the CPT1C 59UTR repression mechanism,
treatment with the AMP agonist AICAR [21,35–43] decreased
reporter activity under glucose deprivation conditions, but not in
FBS deprivation conditions (Fig. 3B).
The AMPK-specific inhibitor, Compound C [35–43], also
induced derepression from the 59UTR, consistent with that seen
for metformin. Curiously, with this compound, higher derepres-
sion of the reporter activity was seen in the FBS deprivation than
in glucose deprivation conditions. The increase in luciferase
activity was a 4.9-fold increase in FBS deprivation, if compared to
a 1.7-fold increase in cells treated with glucose deprivation
(Fig. 3B). We suggest that this effect is likely due to different
pharmacodynamics of Compound C in the presence of serum.
Again, similar results were seen with the alternate cell line SV40-
FHAS (Fig. S4). Analogous to the results shown in Figure 3C,
treatment with the pharmacological inhibitors in combination with
the deprivation media did not affect the luciferase activity in cells
transfected with the mutated 59UTR construct containing no Start
codon (Fig. 3C). Taken together, this data indicates that AMPK
activity likely plays an important role in regulating this
translational repression from the CPT1C 59UTR.
Inhibition of mTOR by Rapamycin did not influence the
CPT1C 59UTR in either of the tested cell lines under either of the
deprivation conditions (Fig. S3). This suggest that the CPT1C
59UTR is responsive to energy supply and not responsive to
stimuli that signal through mTOR.
CPT1C uORF repression is disrupted by AMPK depletion
To test whether the derepression of the reporter activity in
response to the treatment with the chemical AMPK inhibitors
depend on AMPK activity, T98G cells were treated with either an
Figure 2. Modulation of CPT1C 59UTR repression by varied growth conditions. (A) Relative luciferase activities of T98G cells transfected
with the wt uORF reporter gene construct after glucose and/or serum deprivation for 12 h or 24 h. (B) Relative luciferase activities of T98G cells
transfected with the wt uORF reporter gene construct (triangle) or mt uORF reporter gene construct (circle) with titration of glucose concentration in
media after 12 hours. (C) Relative luciferase activities of T98G cells transfected with the no start uORF reporter gene construct after glucose and/or
serum deprivation for 12 h or 24 h. RLU, Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g002
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unspecific control siRNA or siRNAs targeted against AMPKa1
(Table S1). The knock down of AMPKa1 was evaluated 48 h after
transfection in cells maintained in glucose deprivation medium
(Fig. 4A). T98G cell transfected with the 59UTR construct 48 h
after siRNA transfection revealed a derepression of reporter
activity in response to AMPK knockdown (Fig. 4B). The increase
in luciferase activity was similar to that observed after treatment
with the chemical AMPK inhibitors and was not reduced in
response to treatment with the AMPK agonist AICAR. Analogous
to the results shown in Figure 2C and 3C, siRNA transfection did
not affect the luciferase activity in cells transfected with the
mutated 59UTR construct (Fig. 4C). As shown in Figure 4A the
two siRNAs used show a different knock down efficency towards
AMPK alpha 1 protein level. In the Luciferase reporter assay,
however, are similarly effective in derepressing the CPT1C ORF
(Fig. 4B). We hypothesize that a reduction od AMPK alpha 1
beyond a certain threshold will ultimativly lead to a derepression
of CPT1C ORF translation.
Palmitate-BSA treatment releases the CPT1C mORF from
the uORF induced repression
To evaluate the impact of palmitic acid, oleic acid and octanoic
acid on the regulation of the mORF by the uORF, the
transfectants were treated with either 100 mM or 300 mM FA-
BSA. Palmitic and oleic acid are both LCFA and known substrates
of CPT1A and CPT1B, whereas CPT1 protein does not catalyze
import of short chain fatty acid, for example oleic acid, into the
mitochondria [14,26,44]. In normal glucose conditions, treatment
with 100 mM Palmitate-BSA for 12 h led to a 1.9-fold increase in
luciferase activity in T98G cells (Fig. 5A) and 2.6-fold in SV40-
FHAS cells (Fig. S5A), if compared to the untreated control. Here,
the increase in luciferase activity was not maintained over a
Figure 3. CPT1C 59UTR repression is relieved by AMPK inhibition. Relative luciferase activity in T98G cells transfected with uORF start
reporter construct after maintenance in media containing either (A) FBS but no glucose or (B) glucose but no FBS in the presence of AMPK-inhibitors
metformin or Compound C, or in the presence of the AMPK-activator AICAR. (C) Relative luciferase activity in T98G cells and transfected with uORF no
start reporter construct after maintenance in the presence of AMPK-activators metformin or Compound C or the AMPK-inhibitor AICAR. (D) AMPK
phosphorylation status in T98G cells maintained in medium containing FBS but no glucose in the presence of AMPK-activators metformin or
Compound C or the AMPK-inhibitor AICAR. RLU, Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g003
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treatment period of 24 h possibly due to substrate decomposition.
After 12 h of treatment, 300 mM Palmitate-BSA led to a small
further increase over 100 mM treatment levels. At this concentra-
tion, however, a further increase (5-fold above normal) could be
seen after 24 h of treatment. This is equivalent to a 4-fold increase
over 100 mM Palmitate-BSA treatment (Fig. 5A). Furthermore,
SV40-FHAS cells exhibited an 8-fold increase over normal
conditions after 24 h of treatment (Fig. S5B). Treatment with
neither oleic or octanioc acid at the tested FA concentrations
resulted in increased luciferase activity (Fig. 5A). In contrast to the
results shown in Figure 2, 3 and 4 where none of the treatments
did affect the luciferase activity in cells transfected with the
mutated 59UTR, treatment with 300 mM Palmitate-BSA did lead
to a significant decrease of luciferase activity, which suggest a
decrease of transcription in response to the treatment. This
decrease was not observed when the cells where treated with
100 mM Palmitate-BSA or one of the other two FA at either
concentration (Figure 5B). The reduction of transcriptional activity
seen in the 300 mM Palmitate-BSA treated cells suggests that the
translational derepression is stronger than indicated by the fold
change in the wt 59UTR transfected cells (Figure 4A). These data
suggest that there is a concentration sensing and a time-dependent
sensing mechanism used for derepression of the CPT1C 59UTR.
AMPK and Palmitate-BSA regulate CPT1C translation
through independent pathways
Changes in whole-body energy status can be sensed via different
nutrient-sensitive neuronal populations within the hypothalamic
Figure 4. CPT1C 59UTR repression is relieved by AMPK knock down. (A) AMPK mRNA expression in T98G cells treated with either the control
siRNA or the siRNA targeting AMPK maintained in medium containing FBS. (B) Relative luciferase activity in siRNA treated T98G cells transfected with
uORF start reporter construct after maintenance in media containing either glucose but no FBS or FBS but no glucose or FBS but no glucose in the
presence of the AMPK-activator AICAR. (C) Relative luciferase activity in siRNA treated T98G cells and transfected with uORF no start reporter
construct after maintenance in media containing either glucose but no FBS or FBS but no glucose or FBS but no glucose in the presence of the AMPK-
activator AICAR. RLU, Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g004
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feeding centers that react to different sets of stimuli. In order to
examine whether the cellular energy state by the means of AMPK
activity and Palmitate-BSA regulate CPT1C translation via a
common mechanism, T98G cells maintained in media either
containing glucose but no FBS or FBS but no glucose were treated
with the chemical AMPK inhibitors and the AMPK agonist in the
presence of Palmitate-BSA.
Treatment with Metformin or Compound C combined with
Palmitate-BSA, with or without glucose deprivation led to an
additive increase in luciferase activity (Fig. 6A) if compared to the
inhibitor treatment alone (Fig. 3A, B). Treatment with AICAR in
the presence of Palmitate-BSA did not reduce luciferase expression
in cells maintained in glucose deprivation media (Fig. 6A) as it was
observed in cells treated with AICAR alone (Fig. 3A). Analogous
Figure 5. Palmitate relieves CPT1C 59UTR-mediated translational repression. Relative luciferase activity of (A) uORF start and (B) uORF no
start reporter constructs after transfection into T98G cells upon treatment with stated BSA conjugated fatty acids for 12 h or 24 h. RLU, Relative
luciferase units, Palmitate-BSA, Palmitic acid conjugated BSA, Oleate-BSA, Oleic acid conjugated BSA, Octanate-BSA, Octanaic acid-conjugated BSA.
RLU, Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g005
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to the results shown in Figure 2, 3 and 4, the treatment did not
affect the luciferase activity in cells transfected with the mutated
59UTR construct (Fig. 6B). These data suggest that AMPK and
FA may regulate CPT1C translational initiation via independent
mechanisms. Alternately, AMPK, in response to low glucose, may
mobilize FA to ultimately regulate this translational repression.
Discussion
The above data suggest that CPT1C can be regulated through
an uORF and that this regulation can be impacted by cellular
energy availability and AMPK activity. This regulation would
describe a heretofore unseen mechanism for metabolic control of
gene expression. Whereas we would propose that such a
mechanism would have a very limited range of targets, the rate-
limiting role of CPT proteins in FA metabolism would suggest that
it could be physiologically important.
The enzymatic activity of CPT1C remains enigmatic. Although
CPT1C has structural similarities to the other CPT1 isoforms and
binds malonyl-CoA, neither its enzymatic activity nor its
substrate(s) are established [15,17–19]. Indeed the localization of
CPT1C is also controversial, as it has been localized to both the
mitochondria and ER in different studies.
Together with recent evidence for transcriptional control of
CPT1C in the hypothalamus [33], our finding that translational
mechanisms are used to control CPT1C suggests that CPT1C
expression needs to be tightly regulated in the hypothalamus. Our
results indicate that uORF regulation within the 59UTR maintains
low basal CPT1C expression during unstressed conditions and is
important in the translational induction for expression during reduced
energy availability. Regulation at a transcriptional level would suggest
that CPT1C protein levels must rapidly change to fulfil its role.
Combined with the fact that the Cpt1c gene-deficient mouse
demonstrates a metabolic phenotype [15], there is increasing
evidence that CPT1C gene expression may be an important
effector in regulating satiety. Here we provide evidence for a
potential means of regulation of CPT1C by AMPK, a suspected
regulator of satiety. Thus, we offer a novel potential mechanism
for AMPK function in control of satiety. The factors downstream
of CPT1C that may control satiety remain to be elucidated.
Our studies of combining the individual derepressive stimuli
would suggest either these AMPK and FA may act in converging
pathways for CPT1C uORF derepression, or act in a defined
pathway whereby low carbohydrate concentration may signals
AMPK, as is reported. AMPK may then, in turn, mobilize FA that
can then act to derepress the CPT1C uORF. Further biochemical
studies will be necessary to elucidate the specific mechanism
through which Palmitate and AMPK activation may control this
translational derepression.
Materials and Methods
Plasmid construction
The 59UTR of the CPT1C transcript was amplified from the
cDNA clone (MGC, Invitrogen) by PCR under standard conditions
using the following primer (restriction sites are underlined) fwd 59-
CTC GAG GGA ATC GGG GTT TCT GGG TGA CGG-39and
rev 59-AAG CTT GTC ACG CTG GAG CCC ACG and cloned
into a TA vector (Invitrogen). To create a construct lacking a
functional start codon in addition to the wt 59UTR construct, the
ATG of the uORF was mutated to ACG with the following primers
fwd 59-GGC ATT GGA CAT ACG CAA GCG GGA G-39 and
rev 59-CTC CCG CTT GCG TAT GTC CAA TGC C-39 using a
standard side directed mutagenesis PCR. After sequencing, the
Figure 6. Palmitate and AMPK relieve CPT1C 59UTR-mediated translational repression via different pathways. (A) Relative luciferase
activity in T98G cells transfected with uORF start reporter construct after maintenance in media containing either glucose but no FBS or FBS but no
glucose or FBS but no glucose supplemented with the AMPK-inhibitor AICAR. (B) Relative luciferase activity in T98G cells and transfected with uORF
no start reporter construct after maintenance in media either containing glucose but no FBS or FBS but no glucose or FBS but no glucose
supplemented with the AMPK-activator AICAR. RLU, Relative Luciferase Units.
doi:10.1371/journal.pone.0021486.g006
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XhoI/HindIII restricted inserts of both constructs were subcloned
into the phCMV-Cluc-FSR vector (Genlantis).
Preparation of Fatty Acid-BSA complexes
20% essentially fatty acid free BSAwas prepared in 150 mMNaCl
and sterile filtered. 20 mM fatty acid was sapoficated and dissolved in
150 mMNaCl heated up to 65uC. The free fatty acid was complexed
to BSA by adding an equal volume 20% BSA to the 65uC fatty acid
solution and stirred for 10 min. The solution was allowed to cool
down under stirring and sterile filtered before alliquoting.
Cell culture
The human Glioblastoma cell lines T98G and U87-MG and
the SV40 large T-Ag immortalized fetal human non-neoplastic
astrocytic cell line SV40-FHAS were purchased from the
American Type Culture Collection (ATCC). The cells were
maintained in monolayer culture in DMEM containing 4.5 g of
glucose supplemented with 10% FBS, 1% L-Glutamine and 1%
Penicillin/Streptomycin. All cells were grown in a humidified
atmosphere of 5% CO2 at 37uC. For hypoxic conditions, the
T98G cells were cultured at 37uC with 5% CO2, 94% N2 and
0.2% O2 in a hypoxic incubator (Scholzen AG). For all fatty acid
treatments the supplements were added to the normal growth
medium. For the starving conditions either DMEM or DMEM
without glucose supplemented with 1% L-Glutamine and 1%
Penecillin/Streptomycin with and without 10% FBS was used.
T98G cells were transfected with the siRNAs (Tab. S1) using
Lipofectamine 2000 (Invitrogene) using standard protocols 48 h
prior to the Luciferase assay.
Luciferase assay
Cells were co-transfected with the firefly luciferase constructs and
the pRL-SV40 renilla luciferase vector (Promega) using Lipofecta-
mine 2000 (Invitrogene) and seeded 12 h prior to treatment with
104 cells in 96 Micro-Assay-Plates (Greiner-bio-one). Relative
luciferase levels were determined by the ratio of firefly luciferase
and renilla luciferase activity. The luciferase activities were
measured by the Dual-Glo Luciferase System (Promega) according
to the Dual-Glo Luciferase System manual (Promega) using the
Glomax 96-well luminometer (Promega). All experiments were
repeated at least 3 times in triplicates and included Mock
transfections and transfections with the phCMV-cLuc-FSR vector.
Western Blot
Total protein was extracted after irradiation and protein
concentration was determined. 50 mg per sample were separated
by 8% SDS gel and transferred onto PVDF membrane (GE
Healthcare). The membranes were blocked with 2% non-fat-dry
milk and probed with the anti-protein antibodies (AMPKa,
pAMPKa (Thr 172) [Cell Signalling Technology]; tubulin
[SIGMA Aldrich], H5 [SIGMA-Aldrich]). The blots were further
incubated with horse radish peroxidase (HRP)-labeled antibodies
(GE Healthcare) and the specific complexes were detected using
the ECL Western Blotting Detection Reagents (GE Healthcare).
Supporting Information
Figure S1 CPT1C 59UTR induces reporter gene repres-
sion. Luciferase activities of uORF start (filled bars) and uORF no
start (empty bars) reporters in (A) SV40-FHAS cells or (B) U87-
MG cells after transfection and maintenance in normal conditions
for 24 h or 36 h. RLU, Relative Luciferase Units.
(TIF)
Figure S2 Modulation of CPT1C 59UTR repression by
varied growth conditions. Relative luciferase activities of (A,
B) SV40-FHAS cells or (C, D) U87-MG cells transfected with the
wt uORF reporter gene construct after (A, C) glucose and/or
serum deprivation for 12 h or 24 h. (B, D) Relative luciferase
activities of SV40-FHAS cells transfected with the no start uORF
reporter gene construct after glucose and/or serum deprivation for
12 h or 24 h. RLU, Relative Luciferase Units.
(TIF)
Figure S3 Modulation of CPT1C 59UTR repression by
hypoxia and rapamycin. Relative luciferase activities of (A,
B,C) T98G cells or (D, E) SV40-FHAS cells transfected with the
(A; B, D) wt uORF reporter gene construct or with the (C, E) no
start uORF reporter gene construct after (A) 12 h Hypoxia, (A)
12 h Hypoxia and 8 h Reoxigenation or (B, C, D, E) Rapamycin
treatment. RLU, Relative Luciferase Units.
(TIF)
Figure S4 CPT1C 59UTR repression is relieved by
AMPK inhibition. Relative luciferase activity in SV40-FHAS
cells transfected with uORF start reporter construct after mainte-
nance in media containing either (A) FBS but no glucose or glucose
but no FBS in the presence of AMPK-inhibitors metformin or
Compound C, or in the presence of the AMPK-activator AICAR.
(B) Relative luciferase activity in cells and transfected with uORF no
start reporter construct after maintenance in the presence of
AMPK-activators metformin or Compound C, the AMPK-
inhibitor AICAR. RLU, Relative Luciferase Units.
(TIF)
Figure S5 Palmitate relieves CPT1C 59UTR-mediated
translational repression. Relative luciferase activity of (A)
uORF start and (B) uORF no start reporter constructs after
transfection into SV40-FHAS cells upon treatment with stated
BSA conjugated fatty acids for 12 h or 24 h. RLU, Relative
luciferase units, Palmitate-BSA, Palmitic acid conjugated BSA,
Oleate-BSA, Oleic acid conjugated BSA, Octanate-BSA, Octa-
noic acid-conjugated BSA. RLU, Relative Luciferase Units.
(TIF)
Table S1 siRNA sequences. Sequences of the shRNAs used
for transient AMPK knock down and the scarmbeled control
shRNA that was used as a nonspecific control.
(DOC)
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